Groundbreaking research suggests xenon gas could curb Alzheimer’s by reconfiguring brain immune cells

A gas generally known for its inertness and non-reactivity may prove to be a surprising candidate in developing treatments for Alzheimer’s disease. A new study carried out in animal models indicates that xenon, a noble gas, may be the long-awaited discovery.
Xenon is one of six noble gases, named for the Greek word for “strange.” For decades, since the 1950s, the gas has been used in medicine as an anesthetic. More recently, its use has been explored to treat brain injuries and is currently undergoing clinical trials in conditions such as depression and panic disorder.
Scientists at the University of Washington and Brigham and Women’s Hospital, affiliated with Harvard Medical School, both in the United States, conducted research focused on xenon’s potential to address changes occurring in the brains of individuals with Alzheimer’s.
Among the brain changes found in the brains of dementia patients are accumulations of amyloid and tau proteins. Another striking feature of the disease is the loss of synapses, the neuronal connections crucial for functions such as thought, sensation, movement and memory.
An additional change often seen in the brains of people with Alzheimer’s is inflammation, which represents the body’s response to injury or illness and triggers the immune system to repair damaged tissue.
Typically, this inflammation subsides after tissue recovery. However, in Alzheimer’s disease, the inflammatory response persists chronically, leading to immune activation that can compromise healthy brain cells.
The described changes in the brain result in the classic symptoms of Alzheimer’s disease, including memory lapses, disorientation and mood fluctuations.
Although the exact cause of Alzheimer’s is still unknown, a widely accepted theory proposes that the accumulation of amyloid protein initiates a process that culminates in all other pathological changes. For this reason, therapeutic strategies often seek to combat amyloid.
Just over two years ago, for example, the success of a treatment, lecanemab, was reported, which demonstrated the ability to delay the progression of cognitive decline.
However, the formation of protein clusters and synaptic degeneration develop over tens of years, and it is still uncertain whether targeting a single protein, such as amyloid or tau, can effectively halt disease progression or have a significant impact on all the hallmark damage.
The brain is made up of a variety of cells that work together to maintain its complex functions. Neurons, for example, are responsible for vital activities such as walking, speaking, thinking and breathing. Astrocytes provide energetic, structural and protective support to neurons.
Another vital cell type present in brain tissue are microglia. These cells, part of the immune system, play a role in removing pathogens and dead cells. However, its hyperactivity can trigger chronic inflammation in the brain.
Microglia exhibit different states, adapting to the environment in which they find themselves, ranging from inactive to active. The differentiation of these states can be perceived by their morphology and, mainly, by the functions they perform. Active microglia, for example, contribute to the elimination of waste such as unwanted proteins, cells and infectious agents.
In this recent study, scientists employed mice that displayed the same brain changes seen in Alzheimer’s disease to investigate the function of microglia. They identified a specific active state of these cells, linked to inflammation. When exposing animals to inhalation of xenon gas, researchers observed a change in the state of microglia.
This change in cellular state enabled microglia to envelop, engulf, and destroy amyloid deposits. Furthermore, xenon inhalation altered the function of these cells, preventing them from continuing to cause inflammation.
The researchers also documented a decrease in the volume and quantity of amyloid deposits. All of these improvements were directly correlated to the change in the state of microglia.
Promising advances with xenon gas
But what about the other changes often associated with Alzheimer’s? Research has indicated that xenon inhalation can also mitigate brain atrophy, a common feature of the disease, and promote improved neuronal connections. In all rats analyzed, there was a reduction in indicators of excessive inflammation.
In summary, the results of the study suggest that xenon inhalation can induce microglia, which are in an inflammatory state similar to Alzheimer’s, to return to a healthier state, characteristic of a pre-Alzheimer’s brain. This “pre-Alzheimer’s” state favors the removal of amyloid deposits and reduces the production of cellular messengers that trigger excessive inflammation.
There are currently no pharmacological treatments that act directly on microglia to combat Alzheimer’s disease, although progress has been made in controlling amyloid accumulation. Medications already approved to reduce amyloid in the brain offer only a modest reduction in deposits and the speed of cognitive decline.
The effectiveness of amyloid-focused treatments tends to be limited, raising questions about how to address other brain changes such as tau deposits, brain volume atrophy, and synapse loss.
The new research opens a window into an approach that targets a cell type with the intrinsic ability to influence all of these damage characteristic of the disease. This means that rather than attacking just one protein, xenon treatment can rewire the brain’s immune response to counteract a broader spectrum of problems.
Clinical trials in healthy volunteers are expected to begin later this year. If these results are confirmed in humans, xenon could introduce an innovative therapeutic strategy for a disease that profoundly impacts cognitive function. It would be a treatment that does not focus directly on the amyloid protein, but rather on adjusting the brain’s immune response to combat all of the disease’s destructive changes.






